Treatment of melanoma, TNBC and mesothelioma with mAb 9.2.27 [16], mAb 225.28 [18] and TP41.2 [21], respectively, has been shown to suppress CSPG4-mediated cancer progression. This evidence concerns the gene CSPG4 and cancer.